Cover Image
市場調查報告書

脫髮症:開發中產品分析

Alopecia - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 192456
出版日期 內容資訊 英文 156 Pages
訂單完成後即時交付
價格
Back to Top
脫髮症:開發中產品分析 Alopecia - Pipeline Review, H1 2017
出版日期: 2017年02月28日 內容資訊: 英文 156 Pages
簡介

脫髮症是指局部或是完全脫髮,尤其是看得見頭皮,常見於頭部整體或是局部,甚至全身脫毛。最顯著的症狀是頭髮變少。致病因子有過敏、刺激物、毒素、燒燙傷、外傷、感染疾病等。

本報告提供脫髮症的治療藥開發情形調查分析,提供您開發中產品的概要,臨床實驗各階段的產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

脫髮症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品
  • 未確認階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

治療藥的開發企業

  • Bristol-Myers Squibb Company
  • Valeant Pharmaceuticals International, Inc.
  • 大正製藥
  • AntiCancer, Inc.
  • Panacea Biotec Limited
  • ProCertus BioPharm Inc.
  • AndroScience Corporation
  • Hygeia Therapeutics, Inc.
  • Kuhnil Pharmaceutical Co., Ltd.
  • Lee's Pharmaceutical Holdings Limited
  • Berg Pharma, LLC
  • vida therapeutics inc.

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • abatacept
  • ruxolitinib
  • CB-0301
  • calcitriol
  • Small Molecule Antagonists To Transforming Growth Factor Beta Receptor For Alopecia, Pulmonary Fibrosis And Dermatology
  • ZK-003
  • HYG-430
  • HYG-420
  • HYG-410
  • ASCJ-9
  • KI-1104
  • Small Molecule to Inhibit ALK5 for Alopecia and Fibrosis
  • V-2248
  • ProDermaCel
  • Lipo-4MA
  • KI-1105
  • Drug to Agonize P2Y5-Ligand LPA for Alopecia
  • Drug For Autoimmune Disorders
  • Drugs to Inhibit PAI-1 for Thromboembolic Disease, PCOS and Alopecia
  • Peptide For Hair Regeneration

開發中產品的最新趨勢

暫停的計劃

中止開發的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8958IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alopecia - Pipeline Review, H1 2017, provides an overview of the Alopecia (Dermatology) pipeline landscape.

Alopecia is the partial or complete loss of hair especially on the scalp either in patches, on the entire head or over the entire body. Thinning hair is the most obvious symptom. The predisposing factors include allergies, irritants, toxins, burns, injuries, and infections.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alopecia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Alopecia (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alopecia (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Alopecia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 15, 4, 1, 18 and 8 respectively. Similarly, the Universities portfolio in Phase III and Discovery stages comprises 1 and 1 molecules, respectively.

Alopecia (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Alopecia (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Alopecia (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Alopecia (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Alopecia (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Alopecia (Dermatology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Alopecia (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Alopecia (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 4
  • List of Figures 5
  • Introduction 6
  • Global Markets Direct Report Coverage 6
  • Alopecia - Overview 7
  • Alopecia - Therapeutics Development 8
  • Pipeline Overview 8
  • Pipeline by Companies 9
  • Pipeline by Universities/Institutes 12
  • Products under Development by Companies 13
  • Products under Development by Universities/Institutes 16
  • Alopecia - Therapeutics Assessment 17
  • Assessment by Target 17
  • Assessment by Mechanism of Action 20
  • Assessment by Route of Administration 23
  • Assessment by Molecule Type 25
  • Alopecia - Companies Involved in Therapeutics Development 27
  • Aclaris Therapeutics Inc 27
  • Allergan Plc 27
  • Almirall SA 28
  • AndroScience Corp 28
  • Berg LLC 29
  • BiologicsMD Inc 29
  • BirchBioMed Inc 30
  • Bristol-Myers Squibb Company 30
  • Cassiopea SpA 31
  • Concert Pharmaceuticals Inc 31
  • Dong-A Socio Holdings Co Ltd 32
  • Follicum AB 32
  • Handok Inc 33
  • Histogen Inc 33
  • Hyundai Pharmaceutical Co Ltd 34
  • Incyte Corp 34
  • Kuhnil Pharmaceutical Co Ltd 35
  • Lee's Pharmaceutical Holdings Ltd 35
  • LEO Pharma A/S 36
  • Medivir AB 36
  • NovaLead Pharma Pvt Ltd 37
  • Novartis AG 37
  • Panacea Biotec Ltd 38
  • Pfizer Inc 38
  • Quark Pharmaceuticals Inc 39
  • RiverTown Therapeutics Inc 39
  • RXi Pharmaceuticals Corp 40
  • Samumed LLC 40
  • SWITCH Biotech LLC 41
  • Taisho Pharmaceutical Holdings Co Ltd 41
  • Tigo GmbH 42
  • viDA Therapeutics Inc 42
  • Alopecia - Drug Profiles 43
  • (cyclosporine A + minoxidil + RT-175) - Drug Profile 43
  • abatacept - Drug Profile 44
  • AI-001 - Drug Profile 51
  • Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile 52
  • Antisense Oligonucleotide to Inhibit Androgen Receptor for Alopecia - Drug Profile 53
  • ASCJ-9 - Drug Profile 54
  • ATI-50001 - Drug Profile 56
  • ATI-50002 - Drug Profile 57
  • ATI-50003 - Drug Profile 58
  • bimatoprost - Drug Profile 59
  • BMD-1141 - Drug Profile 61
  • BMD-1341 - Drug Profile 62
  • BMD-2341 - Drug Profile 63
  • BQ-A - Drug Profile 64
  • BRM-421 - Drug Profile 65
  • calcitriol - Drug Profile 66
  • CB-0301 - Drug Profile 67
  • CTP-543 - Drug Profile 70
  • DHL-HisZnNa - Drug Profile 72
  • finasteride - Drug Profile 73
  • finasteride - Drug Profile 74
  • FOL-005 - Drug Profile 75
  • HGEN-001 - Drug Profile 78
  • HL-5945 - Drug Profile 80
  • HTB-005 - Drug Profile 81
  • interferon beta-1b - Drug Profile 82
  • KI-1104 - Drug Profile 83
  • KI-1105 - Drug Profile 84
  • LEO-124249 - Drug Profile 85
  • minoxidil - Drug Profile 86
  • NLP-602 - Drug Profile 87
  • OLX-104 - Drug Profile 88
  • PF-06651600 - Drug Profile 89
  • PF-06700841 - Drug Profile 90
  • QPAL-1 - Drug Profile 92
  • QPAL-2 - Drug Profile 93
  • Recombinant Proteins to Antagonize IFN-Gamma Receptor 1 for Alopecia Areata and Graft Arteriosclerosis - Drug Profile 94
  • remetinostat - Drug Profile 95
  • ruxolitinib phosphate - Drug Profile 98
  • Samcyprone - Drug Profile 113
  • secukinumab - Drug Profile 115
  • setipiprant - Drug Profile 128
  • SM-04554 - Drug Profile 130
  • Small Molecule for Androgenic Alopecia - Drug Profile 132
  • Small Molecules to Inhibit JAK for Alopecia Areata, Androgenetic Alopecia and Dermatological Disorders - Drug Profile 133
  • Synthetic Peptide for Alopecia - Drug Profile 134
  • TASP-0382088 - Drug Profile 135
  • TS-133 - Drug Profile 136
  • VTI-1000 Series - Drug Profile 137
  • ZK-003 - Drug Profile 138
  • Alopecia - Dormant Projects 139
  • Alopecia - Discontinued Products 141
  • Alopecia - Product Development Milestones 142
  • Featured News & Press Releases 142
  • Appendix 151
  • Methodology 151
  • Coverage 151
  • Secondary Research 151
  • Primary Research 151
  • Expert Panel Validation 151
  • Contact Us 151
  • Disclaimer 152

List of Tables

  • Number of Products under Development for Alopecia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Alopecia - Pipeline by Aclaris Therapeutics Inc, H1 2017
  • Alopecia - Pipeline by Allergan Plc, H1 2017
  • Alopecia - Pipeline by Almirall SA, H1 2017
  • Alopecia - Pipeline by AndroScience Corp, H1 2017
  • Alopecia - Pipeline by Berg LLC, H1 2017
  • Alopecia - Pipeline by BiologicsMD Inc, H1 2017
  • Alopecia - Pipeline by BirchBioMed Inc, H1 2017
  • Alopecia - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Alopecia - Pipeline by Cassiopea SpA, H1 2017
  • Alopecia - Pipeline by Concert Pharmaceuticals Inc, H1 2017
  • Alopecia - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017
  • Alopecia - Pipeline by Follicum AB, H1 2017
  • Alopecia - Pipeline by Handok Inc, H1 2017
  • Alopecia - Pipeline by Histogen Inc, H1 2017
  • Alopecia - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017
  • Alopecia - Pipeline by Incyte Corp, H1 2017
  • Alopecia - Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2017
  • Alopecia - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017
  • Alopecia - Pipeline by LEO Pharma A/S, H1 2017
  • Alopecia - Pipeline by Medivir AB, H1 2017
  • Alopecia - Pipeline by NovaLead Pharma Pvt Ltd, H1 2017
  • Alopecia - Pipeline by Novartis AG, H1 2017
  • Alopecia - Pipeline by Panacea Biotec Ltd, H1 2017
  • Alopecia - Pipeline by Pfizer Inc, H1 2017
  • Alopecia - Pipeline by Quark Pharmaceuticals Inc, H1 2017
  • Alopecia - Pipeline by RiverTown Therapeutics Inc, H1 2017
  • Alopecia - Pipeline by RXi Pharmaceuticals Corp, H1 2017
  • Alopecia - Pipeline by Samumed LLC, H1 2017
  • Alopecia - Pipeline by SWITCH Biotech LLC, H1 2017
  • Alopecia - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H1 2017
  • Alopecia - Pipeline by Tigo GmbH, H1 2017
  • Alopecia - Pipeline by viDA Therapeutics Inc, H1 2017
  • Alopecia - Dormant Projects, H1 2017
  • Alopecia - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Alopecia - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Alopecia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top